1. Home
  2. QCLS vs INTS Comparison

QCLS vs INTS Comparison

Compare QCLS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

HOLD

Current Price

$1.69

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

N/A

Current Price

$4.10

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
INTS
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
13.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
QCLS
INTS
Price
$1.69
$4.10
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
191.4K
29.3K
Earning Date
04-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
22.33
N/A
EPS
N/A
N/A
Revenue
$3,929,527.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.71
N/A
52 Week Low
$1.76
$0.22
52 Week High
$8.17
$8.06

Technical Indicators

Market Signals
Indicator
QCLS
INTS
Relative Strength Index (RSI) 23.58 42.07
Support Level N/A $3.95
Resistance Level $3.98 $5.09
Average True Range (ATR) 0.18 0.25
MACD -0.04 -0.04
Stochastic Oscillator 1.73 4.24

Price Performance

Historical Comparison
QCLS
INTS

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: